OptimizeRx sees FY26 revenue $109M-$114M, consensus $121.63M

Sees FY26 adjusted EBITDA $21M-$25M. The company said, “We are beginning to see increased market volatility, driven in part by uncertainty surrounding Most Favored Nation pricing. In response, we believe some customers are taking a more measured approach to discretionary spending and contract duration. While this dynamic may create some near-term headwinds, we continue to see solid engagement across our network and remain confident in the underlying demand trends supporting our business.”